Evidence map›Paper›PMID 33236467›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

Collagen release by human hepatic stellate cells requires vitamin C and is efficiently blocked by hydroxylase inhibition.

Natalia Smith-Cortinez, Raphael R Fagundes, Valentina Gomez, Defu Kong, Dirk R de Waart, Janette Heegsma, Svenja Sydor, Peter Olinga, Vincent E de Meijer, Cormac T Taylor and 3 more

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Role of vitamins in the development and treatment of osteoporosis (Review).International journal of molecular medicine · 2025
    Review
  7. Article
  8. Article
  9. High-dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Emerging therapeutic targets in systemic sclerosis.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  14. Article
  15. Article
  16. Structural Insight into the Catalytic Mechanisms of an L-Sorbosone Dehydrogenase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  17. Article
  18. Collagen release by human hepatic stellate cells requires vitamin C and is efficiently blocked by hydroxylase inhibition.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  19. Tobacco Smoking and LiverJournal of oncology · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Natalia Smith-CortinezDepartment of Hepatology and Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Raphael R FagundesDepartment of Hepatology and Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Valentina GomezTytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Defu KongDepartment of Hepatology and Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Dirk R de WaartTytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Janette HeegsmaDepartment of Hepatology and Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Svenja SydorDepartment of Internal Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Peter OlingaDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, the Netherlands.
Vincent E de MeijerDepartment of Surgery, Division of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Cormac T TaylorSchool of Medicine and Medical Science and the Conway Institute, University College Dublin, Dublin, Ireland.
Ruud BankDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Coen C PaulusmaTytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Klaas Nico FaberDepartment of Hepatology and Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NLUniversity of Amsterdam · NLAmsterdam University Medical Centers · NLRuhr University Bochum · DEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is characterized by the accumulation of extracellular matrix proteins, mainly composed of collagen. Hepatic stellate cells (HSCs) mediate liver fibrosis by secreting collagen. Vitamin C (ascorbic acid) is a cofactor of prolyl-hydroxylases that modify newly synthesized collagen on the route for secretion. Unlike most animals, humans cannot synthesize ascorbic acid and its role in liver fibrosis remains unclear. Here, we determined the effect of ascorbic acid and prolyl-hydroxylase inhibition on collagen production and secretion by human HSCs. Primary human HSCs (p-hHSCs) and the human HSCscell line LX-2 were treated with ascorbic acid, transforming growth factor-beta (TGFβ) and/or the pan-hydroxylase inhibitor dimethyloxalylglycine (DMOG). Expression of collagen-I was analyzed by RT-qPCR (COL1A1), Western blotting, and immunofluorescence microscopy. Collagen secretion was determined in the medium by Western blotting for collagen-I and by HPLC for hydroxyproline concentrations. Expression of solute carrier family 23 members 1 and 2 (SLC23A1/SLC23A2), encoding sodium-dependent vitamin C transporters 1 and 2 (SVCT1/SVCT2) was quantified in healthy and cirrhotic human tissue. In the absence of ascorbic acid, collagen-I accumulated intracellularly in p-hHSCs and LX-2 cells, which was potentiated by TGFβ. Ascorbic acid co-treatment strongly promoted collagen-I excretion and enhanced extracellular hydroxyproline concentrations, without affecting collagen-I (COL1A1) mRNA levels. DMOG inhibited collagen-I release even in the presence of ascorbic acid and suppressed COL1A1 and alpha-smooth muscle actin (αSMA/ACTA2) mRNA levels, also under hypoxic conditions. Hepatocytes express both ascorbic acid transporters, while p-hHSCs and LX-2 express the only SVCT2, which is selectively enhanced in cirrhotic livers. Human HSCs rely on ascorbic acid for the efficient secretion of collagen-I, which can be effectively blocked by hydroxylase antagonists, revealing new therapeutic targets to treat liver fibrosis.

Indexed as

ActinsAmino Acids, DicarboxylicAnimalsAscorbic AcidCell LineCells, CulturedCollagen Type ICollagen Type I, alpha 1 ChainHepatic Stellate CellsHumansLiver CirrhosisProlyl-Hydroxylase InhibitorsRatsSodium-Coupled Vitamin C TransportersTransforming Growth Factor betaACTA2 protein, humanActinsAmino Acids, DicarboxylicAscorbic AcidCollagen Type ICollagen Type I, alpha 1 ChainoxalylglycineProlyl-Hydroxylase InhibitorsSodium-Coupled Vitamin C TransportersTransforming Growth Factor betaascorbic acid/vitamin Ccollagen-Ihypoxialiver fibrosismyofibroblast

Identifiers

PMID33236467
PMCPMC12315489
OpenAlexW3110473073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.